Clinical Trials for Cancer Type: Liver

20 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-01-61 A Humanitarian Device Exemption Use Protocol of TheraSphere® HUD For Treatment of Unresectable Primary or Secondary Liver Cancer Open
UCI-03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-15-80 A Phase III Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF /Thymidine Kinase-Deactivated Virus) Followed by Sorafenib versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy Open
UCI-15-81 Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma and Other Gastro-Intestinal Cancers with Liver-Only Metastasis Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-29 Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization Open
UCI-16-40 An Open-Label Multicenter Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma Open
UCI-16-81 Prospective Randomized Trial Comparing Trans-Arterial Chemoembolization Outcome Using Cone Beam CT vs. Conventional Fluoroscopy Open
UCI-16-94 Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti- PD-1 Monoclonal Antibody Open
UCI-16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-107 A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Open
UCI-17-39 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation Open
UCI-17-89 A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma Open
UCI-17-92 TATE versus TACE, an Open-Label Randomized Study Comparing TransArterial Tirapazamine Embolization versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma Open
UCI-17-97 A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) Open
UCI-18-29 Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma Open